Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT06007404
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
175
1
48
3.6

Study Details

Study Description

Brief Summary

This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    175 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance
    Anticipated Study Start Date :
    Sep 1, 2023
    Anticipated Primary Completion Date :
    Sep 1, 2027
    Anticipated Study Completion Date :
    Sep 1, 2027

    Arms and Interventions

    Arm Intervention/Treatment
    Normal weight

    BMI ≥ 5th percentile & < 85th percentile

    Obese weight

    BMI ≥ 95th percentile

    PreDiabetes

    HbA1c > 5.7%

    Outcome Measures

    Primary Outcome Measures

    1. Glucose (OGTT) [120 minutes]

      Plasma Glucose (mg/dL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose

    2. Insulin (OGTT) [120 minutes]

      Plasma Insulin (µU/mL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose

    3. Glucose (MMTT) [180 minutes]

      Plasma Glucose (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake.

    4. Insulin (MMTT) [180 minutes]

      Plasma Insulin (µU/mL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake.

    5. Monocyte /macrophage populations by flow cytometry [180 minutes]

      Frequencies by flow cytometry. Measurements will be taken at baseline sample and 180 minutes after consumption of high fat shake

    Secondary Outcome Measures

    1. Free fatty acids (MMTT) [180 minutes]

      Serum Free fatty acids (mmol/L) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake

    2. Triglycerides (MMTT) [180 minutes]

      Serum Triglycerides (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Between 14 and 18 years of age

    • Tanner stage 5 (mature adult stage of puberty)

    • Normal weight (BMI ≥ 5th percentile & < 85th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes (HbA1c > 5.7%)

    Exclusion Criteria:
    • Currently pregnant

    • Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids)

    • Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability

    • Allergies or intolerance to milk, soy, or palm oil

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Michigan Ann Arbor Michigan United States 48109

    Sponsors and Collaborators

    • University of Michigan
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Investigators

    • Principal Investigator: Kanakadurga Singer, MA, MD, University of Michigan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kanakadurga Singer, Associate Professor, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT06007404
    Other Study ID Numbers:
    • HUM00208301
    • R01DK130864
    First Posted:
    Aug 23, 2023
    Last Update Posted:
    Aug 23, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 23, 2023